MX2020010545A - Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias. - Google Patents
Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias.Info
- Publication number
- MX2020010545A MX2020010545A MX2020010545A MX2020010545A MX2020010545A MX 2020010545 A MX2020010545 A MX 2020010545A MX 2020010545 A MX2020010545 A MX 2020010545A MX 2020010545 A MX2020010545 A MX 2020010545A MX 2020010545 A MX2020010545 A MX 2020010545A
- Authority
- MX
- Mexico
- Prior art keywords
- substance
- disorder
- use disorder
- gaboxadol
- treatment
- Prior art date
Links
- 208000011117 substance-related disease Diseases 0.000 title abstract 6
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 3
- 229950004346 gaboxadol Drugs 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- 235000019788 craving Nutrition 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 208000026251 Opioid-Related disease Diseases 0.000 abstract 1
- 206010043903 Tobacco abuse Diseases 0.000 abstract 1
- 208000025746 alcohol use disease Diseases 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000000380 hallucinogen Substances 0.000 abstract 1
- 240000004308 marijuana Species 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862653641P | 2018-04-06 | 2018-04-06 | |
| US201862654786P | 2018-04-09 | 2018-04-09 | |
| PCT/US2019/026218 WO2019195813A1 (en) | 2018-04-06 | 2019-04-06 | Use of gaboxadol in the treatment of substance use disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010545A true MX2020010545A (es) | 2021-01-08 |
Family
ID=68101544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010545A MX2020010545A (es) | 2018-04-06 | 2019-04-06 | Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190321341A1 (https=) |
| EP (1) | EP3761979A4 (https=) |
| JP (1) | JP2021521103A (https=) |
| KR (1) | KR20210039324A (https=) |
| CN (1) | CN112601524A (https=) |
| AU (1) | AU2019249277A1 (https=) |
| CA (1) | CA3095682A1 (https=) |
| IL (1) | IL277805A (https=) |
| MX (1) | MX2020010545A (https=) |
| WO (1) | WO2019195813A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
| IT1313585B1 (it) * | 1999-07-30 | 2002-09-09 | Neuroscienze S C A R L | Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti. |
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US20020165217A1 (en) * | 2001-05-01 | 2002-11-07 | Pfizer Inc. | Combination treatment for anxiety and depression |
| US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
| BRPI0410857A (pt) * | 2003-06-25 | 2006-07-04 | Lundbeck & Co As H | método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica |
| CL2004001603A1 (es) * | 2003-06-25 | 2005-05-27 | Lundbeck & Co As H | Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico. |
| JP2008538748A (ja) * | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| CN101168058A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 一种混合物制剂 |
| CN101168056A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 混合物制剂 |
| CN101168057A (zh) * | 2006-10-26 | 2008-04-30 | 昆明艾迪康生物科技有限公司 | 多巴胺激动剂制剂 |
| GB0810063D0 (en) * | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
| WO2011069860A1 (en) * | 2009-12-08 | 2011-06-16 | Chr. Hansen A/S | Novel use for the treatment of metabolic endotoxemia |
| WO2012027326A2 (en) * | 2010-08-24 | 2012-03-01 | The Regents Of The University Of California | Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
-
2019
- 2019-04-06 JP JP2020554433A patent/JP2021521103A/ja active Pending
- 2019-04-06 EP EP19781960.0A patent/EP3761979A4/en not_active Withdrawn
- 2019-04-06 CA CA3095682A patent/CA3095682A1/en active Pending
- 2019-04-06 MX MX2020010545A patent/MX2020010545A/es unknown
- 2019-04-06 KR KR1020207032162A patent/KR20210039324A/ko not_active Withdrawn
- 2019-04-06 WO PCT/US2019/026218 patent/WO2019195813A1/en not_active Ceased
- 2019-04-06 CN CN201980037011.8A patent/CN112601524A/zh active Pending
- 2019-04-06 AU AU2019249277A patent/AU2019249277A1/en not_active Abandoned
- 2019-04-06 US US16/377,172 patent/US20190321341A1/en not_active Abandoned
-
2020
- 2020-10-05 IL IL277805A patent/IL277805A/en unknown
-
2022
- 2022-04-19 US US17/723,979 patent/US20220241253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220241253A1 (en) | 2022-08-04 |
| AU2019249277A1 (en) | 2020-10-22 |
| CA3095682A1 (en) | 2019-10-10 |
| CN112601524A (zh) | 2021-04-02 |
| KR20210039324A (ko) | 2021-04-09 |
| EP3761979A1 (en) | 2021-01-13 |
| US20190321341A1 (en) | 2019-10-24 |
| JP2021521103A (ja) | 2021-08-26 |
| EP3761979A4 (en) | 2021-06-30 |
| WO2019195813A1 (en) | 2019-10-10 |
| IL277805A (en) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| WO2020050890A3 (en) | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer | |
| JOP20200001A1 (ar) | كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| MX2020010545A (es) | Uso de gaboxadol en el tratamiento de trastornos por consumo de sustancias. | |
| MX2019014548A (es) | Derivado de n2,n4-difenilprimidin-2,4-diamina, metodo para la preparacion del mismo, y una composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o tratamiento de cancer. | |
| PH12018500532A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MY180847A (en) | Tobacco blend | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| TN2018000422A1 (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| UA120065C2 (uk) | 4,6-ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]-ПІРАЗИНИ ЯК ІНГІБІТОРИ JAK-КІНАЗИ | |
| MY199903A (en) | Combination therapy with controlled-release cnp agonists | |
| PH12018500544A1 (en) | Inhalable nicotine formulations, and methods of making and using thereof | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| UA45271S (uk) | Пристрій для доставляння нікотинвмісного порошку в організм курця | |
| PT3829367T (pt) | Dispositivo para gerar um meio inalável, a sua utilização para fornecer a entrega sustentada de nicotina, cartucho e contentor de composição de tabaco adequado para utilização no mesmo | |
| PH12022550604A1 (en) | Articles and formulations for smoking products and vaporizers | |
| MX2019010263A (es) | Formulaciones de nicotina inhalables y metodos de fabricacion y uso de las mismas. | |
| EP3766364A4 (en) | TOBACCO HUMIDIFIER, METHOD OF MANUFACTURE THEREOF AND ITS USE | |
| ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| EP4265298A3 (en) | Salt | |
| ZA201907101B (en) | Methods of preventing or treating ophthalmic diseases |